Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Glucophage Phase IV protocol release could impede study, Bristol asserts in case brought by HRG.

Executive Summary

BRISTOL GLUCOPHAGE PHASE IV PROTOCOL RELEASE COULD DISRUPT STUDY, ATTORNEY Michael Petty (Fox, Bennett & Turner) asserted on behalf of Bristol-Myers Squibb during a Jan. 27 hearing in D.C. federal court. The hearing was held to consider summary judgment requests in a case brought against FDA by Public Citizen's Health Research Group seeking release of Bristol's protocol for a 10,000-patient study of the oral antidiabetic Glucophage (metformin) under the Freedom of Information Act. Bristol intervened in the suit as a defendant.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029628

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel